Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 3 de 3
Filtrer
Plus de filtres










Base de données
Gamme d'année
1.
J Ovarian Res ; 16(1): 145, 2023 Jul 21.
Article de Anglais | MEDLINE | ID: mdl-37480140

RÉSUMÉ

CONTEXT: Granulosa cells (GCs) that surround oocytes in mammalian reproduction play an active role in oocyte differentiation through proliferation and energy production. AIMS: This study aimed to investigate the characteristics of the energy metabolism of ovarian GCs and the influence of GCs on the early embryonic development in polycystic ovary syndrome (PCOS). METHODS: The clinical characteristics and in vitro fertilization-embryo transfer treatment outcomes of 39 patients with PCOS and 68 patients with simple tubal factor infertility who underwent controlled ovarian hyperstimulation were analyzed and summarized. The mitochondrial function and glucose metabolism level of the GCs were determined, as well as the content of oxidative stress markers in the follicular fluid (FF) of patients with and without PCOS. KEY RESULTS: When compared to the non-PCOS group, patients with PCOS had a significantly increased number of retrieved oocytes but a significantly decreased number of high-quality embryos, available embryos, and high-quality blastocyst formation (P < 0.05). Furthermore, the mitochondrial membrane potential, adenosine triphosphate level, and mitochondrial DNA (mtDNA) copy number decreased in the GCs, whereas the levels of reactive oxygen species increased (P < 0.01). The levels of malondialdehyde and 8-oxo-deoxyguanosine (8-OHdG) in the follicular fluid (FF) of the patients with PCOS were higher than those of the control group (P < 0.05), and superoxide dismutase was increased by compensation (P < 0.05). In the PCOS group, the expressions of GLUT1, LDHA, and PFKP were lower than those in the non-PCOS group, and glucose levels were higher. CONCLUSIONS: The low oocyte competence of PCOS may be associated with mitochondrial dysfunction and abnormal glycolysis. IMPLICATIONS: This research offers explanations for the possible connections influencing human ovarian folliculogenesis.


Sujet(s)
Syndrome des ovaires polykystiques , Grossesse , Femelle , Humains , Syndrome des ovaires polykystiques/métabolisme , Cellules de la granulosa/métabolisme , Transfert d'embryon , Liquide folliculaire/métabolisme , Obésité/métabolisme , Fécondation in vitro , Métabolisme énergétique
2.
Asian Pac J Cancer Prev ; 14(10): 5651-5, 2013.
Article de Anglais | MEDLINE | ID: mdl-24289557

RÉSUMÉ

OBJECTIVE: Major histocompatibility complex class I chain-related A (MICA) is a stress-inducible glycoprotein that can be shed as a soluble protein. This study was conducted to determine the expression of MICA in renal cell carcinoma (RCC) and examine the clinical relevance of soluble MICA (sMICA) in this disease. METHODS: Immunohistochemistry and real-time PCR analyses were performed to assess the expression of MICA in 48 pairs of RCC and adjacent normal renal tissues. Serum levels of sMICA were measured in 48 RCC patients, 12 patients with benign renal tumors, and 20 healthy individuals. The correlations between sMICA levels and clinicopathological parameters were analyzed and the diagnostic performance of sMICA in RCC was evaluated. RESULTS: RCCs exhibited elevated expression of MICA compared to adjacent normal tissues. Serum concentrations of sMICA were significantly greater in RCC patients (348.5 ± 32.5 pg/ml) than those with benign disease (289.3 ± 30.4 pg/ml) and healthy controls (168.4 ± 43.2 pg/ml) and significantly correlated with advanced tumor stage, lymph node metastasis, distant metastasis, vascular invasion, and higher histological grade. Using a cut-off point of 250 pg/ml, sMICA demonstrated a specificity and sensitivity of 63.2% and 75.6%, respectively, in distinguishing between RCC and benign renal tumors. CONCLUSION: MICA expression is upregulated in RCC and increased serum sMICA levels predict aggressive tumor behavior. However, the applicability of sMICA alone is limited in distinguishing RCC from benign renal tumors.


Sujet(s)
Néphrocarcinome/génétique , Néphrocarcinome/métabolisme , Antigènes d'histocompatibilité de classe I/génétique , Antigènes d'histocompatibilité de classe I/métabolisme , Tumeurs du rein/génétique , Tumeurs du rein/métabolisme , Néphrocarcinome/anatomopathologie , Études cas-témoins , Femelle , Humains , Immunohistochimie/méthodes , Tumeurs du rein/anatomopathologie , Métastase lymphatique/génétique , Métastase lymphatique/anatomopathologie , Mâle , Adulte d'âge moyen , Régulation positive/génétique
3.
Chin Med Sci J ; 23(4): 244-8, 2008 Dec.
Article de Anglais | MEDLINE | ID: mdl-19180887

RÉSUMÉ

OBJECTIVE: To evaluate the safety and feasibility of steroid or mycophenolate mofetil (MMF) withdrawal from tacrolimus-based immunosuppressant regimen in renal allograft recipients. METHODS: A cohort of 45 patients following cadaveric renal allograft transplantation were randomly divided into 3 groups based on the regimen of combination of tacrolimus, steroid, and MMF: triple therapy group, steroid withdrawal group, and MMF withdrawal group. During 2 years, survival of patients and allografts, clinical acute rejection, adverse events, hepatic and renal allograft function, and blood lipids were monitored to evaluate the safety and feasibility of steroid or MMF withdrawal after renal transplantation. RESULTS: During two-year observation, steroid or MMF was successfully withdrawn from immunosuppressant regimen based on tacrolimus without any clinical acute rejection. Patient and graft survival rates were 100% and all the renal allografts kept excellent function. Some adverse events occurred and there were no significant differences among groups. CONCLUSION: Withdrawal of steroid or MMF in low-immunological-risk renal allografts treated with tacrolimus-based immunosuppressant regimen can be achieved with no increased risk of acute rejection.


Sujet(s)
Rejet du greffon , Immunosuppresseurs/usage thérapeutique , Transplantation rénale , Acide mycophénolique/analogues et dérivés , Stéroïdes/usage thérapeutique , Tacrolimus/usage thérapeutique , Adulte , Sujet âgé , Association de médicaments , Rejet du greffon/traitement médicamenteux , Rejet du greffon/prévention et contrôle , Humains , Transplantation rénale/effets indésirables , Transplantation rénale/immunologie , Lipides/sang , Adulte d'âge moyen , Acide mycophénolique/usage thérapeutique , Études prospectives , Transplantation homologue/immunologie
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE